Temasek Life Sciences Accelerator

A force multiplier for scientists and innovators pushing the boundaries of what’s possible in biology and beyond. We are a team of biologists, engineers, and reformed finance people, but more importantly, we are... Thought partners Builders Optimists Allies We are here to serve our founders, their teams, and the visions they bring to life. Philosophy In the past decade, humanity has gained the ability to Store data on DNA Reprogram cells to kill cancer Train computers to read medical images Write in the code of life Engineer microbes to fix nitrogen for crops What makes all this possible? The Moore meets Mendel moment What it Means We believe we are in the early chapters of a new biological revolution. Data from novel Bio-Tools plus Artificial Intelligence and Machine Learning are generating major new insights in biology. These insights will create the next generation of biological products. And we upend the way we heal, clothe, consume, and protect. Our processThemes: Sydney Brenner said it best: “Progress in science depends on new techniques, new discoveries and new ideas, probably in that order”. As long-time investors in novel data-generation techniques, we are in a privileged position to identify major new themes and big ideas that emerge from this data. We prioritize areas with high potential for 'first-in-class' or 'best-in-class' applications. Research: We dive deep into our core themes, and focus on identifying major unmet needs. OMX has a mature network of founders, colleagues, and researchers who help us every step of the way to find standout companies and ideas. Select + Invest: When we see clear best-in-class solutions with a clear market fit, we invest early and get to work. We strive to earn the right every day by being reachable and generous with time, while at the same time having the technical and detail orientation to be more than a friendly ear. As part of your due diligence on us, we encourage you to reach out to the founders we have partnered with. Who: Anyone, anywhere! Many of the entrepreneurs who we support are first-time founders. For some, this is their third or fourth go round; and for others yet, this is their third or fourth time working with us.

Willkommen beim Life Science Valley Wachstumsfonds, einem neuen Frühphasen-Risikokapitalfonds mit Sitz in Göttingen, Niedersachsen. Unser Ziel ist es, Innovation im regionalen Ökosystem der Biowissenschaften zu fördern, indem wir vielversprechenden Start-ups und aufstrebenden Unternehmen Finanzmittel und Ressourcen zur Verfügung stellen. Unser Fonds sucht aktiv nach Investitionsmöglichkeiten in einer Vielzahl von Biowissenschaftssektoren, darunter Biotechnologie, Medizintechnik und digitale Gesundheit. Wenn Sie daran interessiert sind, mehr über unseren Fonds zu erfahren oder Ihre Idee vorzustellen, nehmen Sie Kontakt mit uns auf. Wir freuen uns auf die Zusammenarbeit mit Ihnen, um die Zukunft der Life-Science-Innovation in Niedersachsen und darüber hinaus zu gestalten. Investmentfokus Der frühphasige Fonds für Life Science Technologieausgründungen in Niedersachsen Der Fonds in Niedersachsen um die lokalen kommerziellen und unternehmerischen Potenziale der exzellenten Life Science Forschung und Technologien zu heben. Unterstützung von frühphasigen, nieder-sächsischen Unternehmen in den Bereichen BioTech, MedTech, Digital Health und Agriscience. Förderung erfolgreicher Unternehmensgründungen in technologischen Wachstumsfeldern. Inhaltlicher Fokus auf Life Sciences und klare Investmentkriterien als Basis für Erfolg Niedersächsische Life Science Unternehmen, u.a.: Biotechnologische Wirkstoffentwicklung und Verfahren Neuartige Schlüsseltechnologien in der Bio-Medizin, Medizintechnik, Diagnostik und Molekularbiologie (Digital) Life Science Tools für Entwicklung und Produktion von medizinischen Wirkstoffen sowie pflanzlichen Traits (Digitale) Tools zur Verbesserung von klinischen Prozessen Extended Life Sciences, z. B. Agri-Life Sciences, Human Mobility Solutions, etc. Markt: Nachweisbarer klinischer Bedarf „unmet medical/clincial need“ bzw. Marktbedarf Team: Interdisplizinäres und unternehmerisches Team mit hoher wissenschaftlicher, technologischer und wirtschaftlicher Kompetenz Synergiepotenziale: Hohes Potential für Zusammenarbeit und Kollaboration zwischen dem Start-up, relevanten Partnern im Ökosystem und unserem Fonds-Team Umsetzbarkeit: Klar definierter Entwicklungspfad bis zur Marktreife Value Proposition: Nachhaltige Alleinstellung gegenüber potenziellen Wettbewerbern z.B. über gesicherte IP Finanzierbarkeit: Realistische Finanzierbarkeit des weiteren Entwicklungsverlaufs

Pioneers in deploying venture capital into high impact agrifood tech since 2014, we back ambitious teams that are reconnecting and strengthening the link between human health and the health of the planet through innovative technology. Clay Capital was founded with the belief that food is both the cause of, and remedy to, some of today’s most urgent challenges: environmental degradation, societal inequity, and human health. We see these issues as interconnected.In Europe and Asia especially, there is a generation of entrepreneurs motivated to tackle the $12 trillion market opportunity that lies in restoring and reconnecting human and planetary health - and who have a toolkit fit for purpose: from farmers and chefs, to biotechnologists, computational biologistics, plant scientists, computer engineers and multidisciplinary teams merging these skillsets. There is no single silver bullet; transforming a system that has supported humanity in its evolution from Nomadic to Agrarian, and been the seed that rooted and grew societies around the globe, will not happen overnight. Therefore, there’s an urgent need for both transitional solutions and revolutionary new infrastructure. We aim to back both, and enable a healthier food system to co-exist with a healthier planet within our lifetimes. Clay Capital invests to strengthen and refocus how materials are produced and consumed through innovation to have sustainable, nutritious, and circular outcomes. This context presents us with unrivalled opportunities for smart investing - investments that address urgent issues today, for a better tomorrow.

Industrifonden is a venture capital fund backing transformative ventures with the power to change the way we live for the better. We look for unique, scalable innovations that have a meaningful impact on our society. Industrifonden was founded by the Swedish government in 1979 as an independent foundation to provide Swedish industry with an innovation growth engine. For more than forty years, we have partnered with high-tech ventures in deep tech, life science, and transformative business. Today, we are an independent venture capital fund continuing our legacy by partnering with innovators and entrepreneurs to bring Nordic breakthrough innovations to the world. We partner with passionate founders that can turn their ideas into reality and change the industry – or create a totally new one. We primarily invest in Swedish innovations, as well as the Life Science and Deep Tech industries across the Nordics. At Industrifonden, we focus less on short-term wins and more on successful long-term investments that will create lasting value and benefits to our society. We’re in it for the long run, because experience has taught us that developing fundamental innovations takes time. Our areas of expertiseDeep Tech: We invest in advanced technology that addresses important societal issues. We have a special interest in advanced materials, industry 4.0, energy, advanced computing, AI, and synthetic biology. Life science: We invest in the commercialization of products and services, grounded in solid science, which address an unmet medical need. We have expertise in biotech, medtech and healthtech. Transformative tech: We invest in transformative tech and business models to create the industry of tomorrow. We mostly stay within the B2B space but invest in a broad range of industry verticals. Seed to A-round funding We invest in early-stage companies, from seed to A-round funding, and sometimes earlier. Our first ticket is often 10-50 million SEK, with the capacity to invest considerably more during the lifecycle. Smaller tickets are also considered in an earlier stage for exceptional technologies. In it for the long run Our fund has an evergreen structure allowing us to focus less on short-term wins and focus more on investments that will create long-term value. What we look for Unique, scalable innovations that have a meaningful impact on our society. Passionate founders that can turn their ideas into reality. Ideas with the potential to change a whole industry – or create a new one. If this sounds like you, share your pitch deck with us! Your pitch deck should include a clear problem statement, unique solution, target market, business model, team, financial projections, roadmap, cap-table and a clear ask. We value creativity, innovation, and collaboration.

Our unique model combines first access and proprietary rights to disruptive deal flow with an established track record of new venture formation, company building, and value creation. We invest in bold, transformative innovations to develop new drugs and technologies to improve outcomes for the market benefit of patients worldwide. Investing in early-stage venture capital We invest in seed and early-stage life science ventures, bringing Mass General Brigham’s expertise and extensive network to bear to create transformative solutions to solve unmet medical needs. Leveraging a competitive advantage Research is the driving force that advances medicine and Mass General Brigham Ventures sits at the center of the largest medical research engine in the United States. #1 in hospital medical research​ Mass General Brigham Ventures is a member of the largest hospital system-based research enterprise in the U.S., which includes Massachusetts General Hospital and Brigham and Women’s Hospital, two of the nation’s premier academic medical centers whose origins date back to the early 1800’s.​ Mass General Brigham Ventures' unique model leverages a preferred position to source technology including first access and rights to disruptive deal flow. This is an exceptional advantage that conventional venture capital funds cannot reproduce. Legacy of investing in medical innovation Mass General Brigham Ventures plays a key role in founding and funding next-generation technologies. These three transformational companies are examples of start-ups that are poised to address significant unmet medical needs. All were seeded by Mass General Brigham Ventures with founding intellectual property from Mass General Brigham. Editas Medicine: IPO Feb. 2016 (NASDAQ: EDIT) Unlocking the power and potential of CRISPR genome editing technology. CoStim Pharmaceuticals: Acquired by Novartis, Feb. 2014 Next-generation immuno-oncology drugs based on T-cell costimulatory targets. Keros Therapeutics: IPO April 2020 (NASDAQ: KROS) Novel treatments for patients suffering from hematologic and musculoskeletal disorders. Our investment strategy We invest in next-generation life science companies based on intellectual property created within our own research community. We seek strong co-investor syndicates to develop products across a range of categories including drugs, devices, diagnostics, and digital health.​ Initial investments are directed at the seed and Series A stages, where our participation attracts capital and talent into the most difficult-to-fund phase of company development. When we invest, we expect to support each portfolio company through its entire financing lifecycle. In addition to providing the necessary venture capital, we leverage our experience in starting and growing companies, our expertise in the medical industry, and our network of scientific and business talent to build great companies. Leveraging a proven approach:The annual output of high-impact invention and discovery represents a unique opportunity to create, finance, and monetize new life science-based companies. We deploy start-up capital to capture the collective expertise of our unrivaled base of scientific talent and clinical resources to bring cutting-edge science to patients Competitive advantage of Mass General Brigham: The power of collective impact from our vast research enterprise provides an unrivaled competitive advantage to build next generation life science companies capable of bringing innovative therapeutics to patients in need and delivering outstanding returns to our investors. Academic medical centers: We source deals from our five research and teaching hospitals, which collectively represent the largest teaching affiliate of Harvard Medical School.

We invest in the innovators behind the miracles of science who are passionate about improving human health. Sanofi Ventures serves as an entry point to the innovation ecosystem for Sanofi, strategically investing in early-stage transformational science and technology, when companies are too early to partner with or acquire. Our Approach As the corporate venture capital arm of Sanofi, we invest in top-tier biotech and digital health companies that focus on helping patients and transforming the practice of medicine. We invest across all stages of the private company lifecycle, from Seed to Series B and beyond, while leading financings, serving on boards, and taking pride in working alongside portfolio companies to drive long-term value through future financings and IPO. How We Work Think of us like institutional venture capitalists with an added bonus: in addition to our investment, we aim to offer our portfolio companies select access to Sanofi’s expertise and capabilities in science, preclinical and clinical development, regulatory, data analytics, manufacturing, market access, and commercialization. Our goal is to foster strong relationships over time so when our portfolio company is ready to consider a partnership or acquisition, our colleagues on the BD and M&A teams can be a first and last call. We move quickly, we don’t believe in drawn-out processes, and we always aim to provide thoughtful feedback. Our Investment Focus We invest in early-stage biotech and digital health companies of strategic interest to Sanofi. We seek to accelerate all strategic focus while reaching into novel and emerging areas of science and technology. Here are some of the areas that we currently are thinking about: Rare diseases Immunology and inflammation Oncology Cell and gene therapy Vaccines Digital health and data science We can't do it alone - we would love to hear how we can team up to improve human health for people everywhere!